Pfizer covid-partner BioNTech has almost €19bn in cash for cancer and other diseases           

Company also working on other vaccines against infections such as tuberculosis and shingles

Last week, the World Health Organization ended the global emergency status for covid.

Germany's BioNTech, Pfizer's partner on covid vaccines, has said its first-quarter profit plunged on lower demand for the shots as it widens its work on cancer and other diseases.

BioNTech, which reported it had built up an €18.6bn balance of cash and receivables at the end of March, has pursued a string of takeovers and alliance deals to broaden its work on cancer treatments.